- Home
- OPCH vs CYTK Comparison
OPCH vs CYTK Comparison
Compare OPCH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- CYTK
- Stock Information
- Founded
- OPCH N/A
- CYTK 1997
- Country
- OPCH United States
- CYTK United States
- Employees
- OPCH N/A
- CYTK N/A
- Industry
- OPCH Medical/Nursing Services
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- OPCH Health Care
- CYTK Health Care
- Exchange
- OPCH Nasdaq
- CYTK Nasdaq
- Market Cap
- OPCH 5.3B
- CYTK 5.6B
- IPO Year
- OPCH N/A
- CYTK 2004
- Fundamental
- Price
- OPCH $31.70
- CYTK $32.00
- Analyst Decision
- OPCH Strong Buy
- CYTK Buy
- Analyst Count
- OPCH 7
- CYTK 15
- Target Price
- OPCH $35.86
- CYTK $73.71
- AVG Volume (30 Days)
- OPCH 1.6M
- CYTK 2.0M
- Earning Date
- OPCH 04-29-2025
- CYTK 05-06-2025
- Dividend Yield
- OPCH N/A
- CYTK N/A
- EPS Growth
- OPCH N/A
- CYTK N/A
- EPS
- OPCH 1.25
- CYTK N/A
- Revenue
- OPCH $5,185,122,000.00
- CYTK $19,218,000.00
- Revenue This Year
- OPCH $13.22
- CYTK $24.01
- Revenue Next Year
- OPCH $8.52
- CYTK $698.33
- P/E Ratio
- OPCH $25.18
- CYTK N/A
- Revenue Growth
- OPCH 16.98
- CYTK 412.21
- 52 Week Low
- OPCH $21.39
- CYTK $29.31
- 52 Week High
- OPCH $35.53
- CYTK $61.38
- Technical
- Relative Strength Index (RSI)
- OPCH 45.26
- CYTK 44.20
- Support Level
- OPCH $31.34
- CYTK $30.02
- Resistance Level
- OPCH $32.94
- CYTK $31.27
- Average True Range (ATR)
- OPCH 0.68
- CYTK 1.32
- MACD
- OPCH -0.03
- CYTK 0.38
- Stochastic Oscillator
- OPCH 24.19
- CYTK 72.12
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.